DEXCOM INC (DXCM) Stock Overview
USA - NASDAQ:DXCM - US2521311074 - Common Stock
DXCM Key Statistics, Chart & Performance
The current stock price of DXCM is 69.23 USD. In the past month the price increased by 2.88%. In the past year, price decreased by -1.59%.
DXCM Latest News, Press Relases and Analysis
DXCM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.37 | 220.36B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.34 | 195.51B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.23 | 149.61B | ||
| SYK | STRYKER CORP | 29.26 | 143.72B | ||
| MDT | MEDTRONIC PLC | 16.86 | 119.59B | ||
| BDX | BECTON DICKINSON AND CO | 12.91 | 52.80B | ||
| IDXX | IDEXX LABORATORIES INC | 52.82 | 50.75B | ||
| EW | EDWARDS LIFESCIENCES CORP | 31.98 | 48.25B | ||
| RMD | RESMED INC | 26.87 | 37.44B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.04 | 36.25B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.35 | 26.29B | ||
| STE | STERIS PLC | 25.28 | 23.76B |
Related stock screener links
About DXCM
Company Profile
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 10,300 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Company Info
DEXCOM INC
6340 Sequence Drive
San Diego CALIFORNIA 92121 US
CEO: Kevin R. Sayer
Employees: 10250
Phone: 18582000200
DEXCOM INC / DXCM FAQ
Can you describe the business of DEXCOM INC?
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 10,300 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
What is the current price of DXCM stock?
The current stock price of DXCM is 69.23 USD. The price decreased by -1.98% in the last trading session.
What is the dividend status of DEXCOM INC?
DXCM does not pay a dividend.
How is the ChartMill rating for DEXCOM INC?
DXCM has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What do analysts say about DEXCOM INC (DXCM) stock?
35 analysts have analysed DXCM and the average price target is 104.5 USD. This implies a price increase of 50.94% is expected in the next year compared to the current price of 69.23.
Can you provide the number of employees for DEXCOM INC?
DEXCOM INC (DXCM) currently has 10250 employees.
What is the outstanding short interest for DEXCOM INC?
The outstanding short interest for DEXCOM INC (DXCM) is 2.98% of its float.
DXCM Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to DXCM. When comparing the yearly performance of all stocks, DXCM is a bad performer in the overall market: 80.55% of all stocks are doing better.
DXCM Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to DXCM. While DXCM has a great profitability rating, there are some minor concerns on its financial health.
DXCM Financial Highlights
Over the last trailing twelve months DXCM reported a non-GAAP Earnings per Share(EPS) of 1.7. The EPS decreased by -2.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.29% | ||
| ROA | 7.8% | ||
| ROE | 22.21% | ||
| Debt/Equity | 0.5 |
DXCM Forecast & Estimates
35 analysts have analysed DXCM and the average price target is 104.5 USD. This implies a price increase of 50.94% is expected in the next year compared to the current price of 69.23.
For the next year, analysts expect an EPS growth of 26.8% and a revenue growth 14.99% for DXCM